On June 24, 2024, Avenue Therapeutics, Inc. held its annual meeting of stockholders where several key decisions were made. The stockholders approved an amendment to the 2015 Incentive Plan, increasing the number of shares authorized for issuance by 5 million, extending the plan's term to 2034, and raising the annual share limit for non-employee director awards to 500,000. The Board of Directors had previously approved this amendment, which took effect upon stockholder approval. Additionally, six directors were elected to serve until the 2025 annual meeting, and KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The meeting was conducted virtually with a quorum present, representing a majority of the outstanding voting power. The detailed results of the voting on directors, the accounting firm ratification, and the 2015 Plan Amendment were disclosed, with the majority of votes cast in favor of all proposals.

On June 24, 2024, Avenue Therapeutics, Inc. held its annual meeting of stockholders where several key decisions were made. The stockholders approved an amendment to the 2015 Incentive Plan, increasing the number of shares authorized for issuance by 5 million, extending the plan's term to 2034, and raising the annual share limit for non-employee director awards to 500,000. The Board of Directors had previously approved this amendment, which took effect upon stockholder approval. Additionally, six directors were elected to serve until the 2025 annual meeting, and KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The meeting was conducted virtually with a quorum present, representing a majority of the outstanding voting power. The detailed results of the voting on directors, the accounting firm ratification, and the 2015 Plan Amendment were disclosed, with the majority of votes cast in favor of all proposals.